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Abstract
Disorders of mineral metabolism and bone disease are common complications in CKD 
patients. They are very complex and involve a number of feedback loops between the kid-
ney, bone, intestine, and the vasculature associated with an increased morbidity and mor-
tality and decreased quality of life of the patients. The work group of the kidney disease: 
Improving Global Outcomes (KDIGO) recommended in 2006 the use of the term chronic 
kidney disease-mineral and bone disorder (CKD-MBD) to describe a systemic disorder that 
incorporates these abnormalities. Compared to hemodialysis (HD), patients undergoing 
peritoneal dialysis (PD) appear to have an increased prevalence of low turnover bone disease 
defined as adynamic bone disease (ABD). The most important risk factors for ABD are age, 
oversuppression of parathyroid hormone (PTH) with vitamin D, diabetes, circulating antag-
onist PTH fragments, and frequent presence of a positive calcium balance, which may result 
in an oversuppression of PTH. PTH levels and bone phosphatase alkaline (bALP) should be 
assessed among such patients as the earliest markers of abnormal mineral and bone metabo-
lism. Treatments considered are interventions to treat hyperphosphatemia, hyperparathy-
roidism, and bone disease. The optimal management of chronic kidney disease-mineral and 
bone disorder (CKD-MBD) includes the prevention of vascular calcifications.
Keywords: peritoneal dialysis, phosphate, calcium, adynamic bone disease, 
hyperparathyroidism
1. Introduction
Chronic kidney disease (CKD) is a global public health problem affecting 5–10% of the world 
population [1]. Disorders of bone and mineral metabolism and vascular calcification have been 
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identified as major risk factors for cardiovascular morbidity and mortality in patients with 
CKD. In the course of CKD appears a reduction in the ability of the kidney to excrete an adequate 
load of phosphate which leads to hyperphosphatemia. At the same stages of CKD in which phos-
phorus retention appears to occur, we are faced with calcium retention too. The main hormones 
and factors that contribute to the kidney regulation of phosphorus and calcium include parathy-
roid hormone (PTH), fibroblast growth factor 23 (FGF-23), klotho and 1,25-dihydroxyvitamin D 
(1,25(OH)2D). It is now accepted that the increase in FGF-23 is an early event in the pathogenesis 
of mineral disorders in CKD. FGF-23 levels increase early in CKD, and may reflect an increased 
phosphorus load. This adaptive change favors the reduction of kidney 1-alpha-hydroxylase, 
which in turn results in lower levels of the active form of vitamin D 1,25(OH)2D3, decreasing 
intestinal calcium absorption and allowing a decrease in serum calcium. These changes allow 
increased PTH synthesis and its release. High level of PTH increases bone turnover and bone 
resorption, stimulates 1-alpha-hydroxylase, and increases phosphorus removal through reduc-
ing its kidney tubular resorption. Although FGF-23 and PTH having synergic effects regard-
ing phosphorus removal, they have opposite effects on 1,25(OH)2D3 synthesis by inhibiting or 
stimulating 1-alpha-hydroxylase, respectively. During late Stage 4 CKD and into end-stage renal 
disease (ESRD), all these mechanisms become insufficient and most patients show hyperphos-
phatemia, high PTH, marked elevations of FGF-23, and reductions of klotho and 1,25(OH)2D3 
[2–4]. All these changes together are critically important in the regulation of both initial bone for-
mation during growth (bone modeling) and bone structure and function during adulthood (bone 
remodeling) [5]. High serum phosphorus was considered the most important uremia-related, 
non-traditional cardiovascular risk factor so controlling hyperphosphatemia was considered one 
of the most important goals in managing bone disorders in CKD patients [1].
Effective dietary phosphate restriction has resulted difficult in clinical practice so the use of 
phosphate binders has become the mainstay of efforts to decrease phosphate absorption from 
the intestine. The generalized usage in the past of aluminum-containing phosphate binders 
and calcium-containing phosphate binders was reported to be associated with increased 
incidence of adynamic bone disease (ABD) [6]. The mineral and hormonal changes in CKD 
patients go beyond bone alterations and are responsible for systemic consequences such as 
vascular calcification [1]. These changes have a major impact on morbidity and mortality 
[7] and consequently their control is of great importance in CKD patients. This chapter is a 
review that briefly discusses etiology, pathophysiology diagnosis of mineral bone disorders in 
chronic kidney disease patients on treatment with peritoneal dialysis and therapeutic options.
2. Overview on bone disease and mineral metabolism disorders in 
peritoneal dialysis patients
2.1. Etiology and pathogenesis
Disorders of mineral metabolism and bone disease are common complications in CKD 
patients. They are very complex and involve a number of feedback loops between the kidney, 
bone, intestine, and the vasculature. These are associated with numerous adverse clinical out-
comes, in particular cardiovascular disease and increased fracture risk [8] which contributes 
in an increased morbidity and mortality and decreased quality of life of the patients [3].
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The work group of the kidney disease: Improving Global Outcomes (KDIGO) recommended 
in 2006 the use of the term chronic kidney disease-mineral and bone disorder (CKD-MBD) to 
describe a systemic disorder that incorporates these abnormalities [9]. These systemic distur-
bances may manifest themselves by the presence of any one or a combination of the following 
three conditions: (1) laboratory abnormalities of calcium, inorganic phosphorus, PTH or vita-
min D; (2) bone abnormalities in turnover, mineralization, volume, linear growth or strength, 
and (3) calcification of the vasculature or other soft tissues [8].
The work group recommended that the traditional term “renal osteodystrophy” be exclu-
sively used to define alterations in bone morphology associated with CKD and stated that 
definitive diagnosis of renal osteodystrophy can only be made by bone biopsy [1].
It is well known that the traditional types of renal osteodystrophy have been defined on the 
basis of turnover and mineralization, with substantial differences in pathophysiology and 
treatment.
• Bone turnover and bone volume may both be classified as high, normal or low.
• Bone mineralization may be categorized as normal or abnormal.
In this way, it was suggested that bone biopsies in patients with CKD should be characterized 
by determining bone turnover (T), mineralization (M), and volume (V) (the TMV system) [9].
Six types of bone disorder are distinguished in the CKD-MBD complex [9]: hyperparathyroid 
bone disease (high turnover, normal mineralization, and any bone volume); mixed bone dis-
ease (high turnover with mineralization defect and normal bone volume); osteomalacia (low 
turnover with abnormal mineralization and low-to-medium bone volume); ABD (low turnover 
with normal mineralization and low or normal bone volume); and two distinct disorders due 
to specific causative agents, namely, amyloid bone disease and aluminum bone disease [10].
While the majority of studies focusing on CKD-MBD in dialysis patients involved hemodi-
alysis (HD) patients, relatively few studies involving peritoneal dialysis (PD) patients have 
been published [1, 10]. It has been argued that features of CKD-MBD differ between patients 
undergoing PD and HD, secondary hyperparathyroidism remains the most common pattern 
in HD patients, and adynamic bone disease was more frequent in patients on PD [1]. This 
is based on a systematic review which analyzed studies carried out between 1983 and 2006 
(Table 1). These findings strengthened the worldwide belief that PD is an important risk fac-
tor for ABD development.
ABD was first described in association with aluminum overload, being in the past the major 
cause of this bone lesion [11]. Aluminum deposition along the calcification fronts prevents the 
mineralization process and also inhibits the deposition of osteoid by directly damaging the 
osteoblasts [12].
Although there is a large difference between current and past clinical practice and patient 
characteristics regarding PD treatment (common use of aluminum- and calcium-based phos-
phate (P) binders, or PD modality mainly for elderly patients), in recent studies, bone his-
tomorphometry persists to reveal lower turn-over parameters and worst mineralization in 
peritoneal dialysis patients when compared to hemodialysis ones [13, 14].
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Over time, it became apparent that adynamic bone or low bone formation exists without 
aluminum overload and became associated with abnormal calcium balance, the low levels of 
1.25 dihydroxyvitamin D, metabolic acidosis, in addition to low levels of estrogen and pro-
gesterone, and systemic inflammation. It is referred to be linked with calcific arteriolopathy 
and cardiovascular disease (CVD) [15, 16].
There are a lot of specific factors which are reported to contribute in the pathogenesis of ABD 
in peritoneal dialysis:
• Accumulation of advanced glycation end products (AGEs) proteins reported in diabetes 
was also observed in PD patients. This happens during heat sterilization of PD conven-
tional fluids, where glucose is degraded into products that include reactive carbonyl 
compounds [17]. Serum from uremic patients was also shown to contain high levels of 
these compounds derived not only from carbohydrates but also from lipids. The genera-
tion of high quantities of AGEs and advanced lipid end products modify bone matrix and 
participate in the processes which lead to the development of ABD [18]. In addition of 
elevated AGEs, PD patients have impaired glucose tolerance and high glucose levels dur-
ing explosion to high glucose concentrations. High glucose levels were reported to inhibit 
bone mineralization in vitro by preventing calcium uptake by bone cells [19], a finding that 
could further support the altered bone structure in diabetic patients.
• High levels of calcium and magnesium found in dialysate. High magnesium concentra-
tions may inhibit parathyroid hormone secretion just as high calcium concentrations do 
[20], being involved in the pathogenesis of adynamic bone in PD patients [21].
• Sclerostin is another factor with impact on ABD in PD patients. Sclerostin is a glycoprotein 
(22 kDa) product of the SOST gene in osteocytes, which leads to a negative regulation of 
bone formation by inhibiting differentiation and proliferation of osteoblasts. Recent inves-
tigations, demonstrated that increased plasma levels of sclerostin, were found to be associ-
ated with reduced bone turnover and osteoblast proportion in dialysis patients [14, 22].
• In PD patients, we are faced with high prevalence of hypoalbuminemia which came as a 
result of loss through the peritoneal membrane or malnutrition. It is reported that low level of 
albumin contributes to the development of ABD by reducing the plasma level of PTH. Serum 
intact PTH has been shown to positively correlate with serum albumin in PD patients [23].
PD HD
Adynamic bone disease 50% 19%
Mild disease 20% 3%
Osteitis fibrosa 18% 34%
Mixed bone disease 5% 32%
Osteomalacia 5% 10%
Normal bone histology 2% 2%
Table 1. Prevalence of types of bone disease as determined by bone biopsy in patients with CKD-MBD.
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The relationship between low PTH level, ABD, increased fracture risk [24], and vascular calci-
fications may at least partially explain the association of ABD with increased mortality rates. 
To achieve optimal bone and cardiovascular health, attention should be focused not only on 
classic control of secondary hyperparathyroidism but also on prevention of ABD, especially 
in the steadily growing proportions of diabetic, white, and elderly patients in PD [25].
2.2. Phosphate retention and hyperphosphatemia
It is generally accepted that the accumulation of phosphorus appears to begin in CKD Stage 
3b and contributes to secondary hyperparathyroidism [3]. Persistent stimulation of the 
parathyroid glands by elevated extracellular phosphorus concentrations, especially when 
is accompanied by decreased extracellular ionized calcium concentrations, and markedly 
reduced serum calcitriol levels leads to increased parathyroid hormone (PTH) production 
[26]. This promotes diffuse polyclonal hyperplasia followed by monoclonal nodular hyper-
plasia, decreases the levels of calcium-sensing receptor and vitamin D receptor, lowering the 
activity of 1-alpha-hydroxylase and consequently decreases serum 1,25(OH)2D3 levels [27].
In severe hyperparathyroidism, hyperphosphatemia may be worsening via phosphorus 
efflux from the skeleton compromising its phosphorus reserve capacity. On the other side, in 
low bone turnover, the size of the exchangeable calcium and phosphorus pool is reduced and 
also is drastically reduced the buffer capacity of the skeleton for the excess of phosphorus. In 
this way, hyperphosphatemia links vascular calcification with low bone turnover.
Phosphate excess also has reported to be linked with endothelial dysfunction [28] and ele-
vated FGF23, which contributes to left ventricular hypertrophy [29], being so an independent 
risk factor for mortality in ESRD [2].
Phosphate enters the body by intestinal absorption and is excreted through stools and dialy-
sis fluids (plus urine output in patients with residual renal function). In dialysis patients, 
elimination of the inorganic phosphate by dialysis is a cornerstone of the management of 
hyperphosphatemia. The elimination characteristics of phosphate in HD and PD are unlike 
the urea and other low molecular weight toxins much more similar to those of typical middle 
molecules although the molecule is only 96D. This is explained with its negative charge, the 
aqueous cover that increases its effective molecular weight, and the slow intra/extracellular 
solute transfer rate [30].
In the case of daily dialysis or long nocturnal dialysis, P mass removal is usually large enough 
to reduce the need of dietary restrictions and the use of P binders. It does not happen in the 
case of well-nourished patients on standard three-times-a-week dialysis schedule, where to 
achieve a good P balance is needed an optimal dialysis removal, careful use of phosphate 
binders, and dietary P control [31].
Some studies suggest that continuous PD may be better in controlling hyperphosphatemia 
than intermittent hemodialysis [32–35]. This observation supports thesis that PD provides bet-
ter phosphorus clearance through better preservation of renal failure and its continuous nature.
At the start of PD therapy, residual renal function (RRF) may contribute up to 65% of total 
phosphate clearance [30, 35]. Urinary phosphate excretion is found to highly correlate with 
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residual renal function and also a strong correlation between RRF and serum phosphate con-
centration on PD has been reported [32, 35]. It is well known that RRF declines with time on 
PD and the effect of this decline on phosphate homeostasis has been described in a few obser-
vational studies [34, 36, 37]. Phosphate removal is shown to correlate strongly with residual 
renal function, but it is dissociated from peritoneal Kt/V urea, creatinine clearance, and net 
ultrafiltration. Peritoneal creatinine transporter status and creatinine clearance cannot be used 
as surrogate markers of peritoneal phosphate transport and clearance. Prescription of high vol-
ume of dialysate is one of the strategies recommended to increase P removal in anuric patients 
[30]. Hyperphosphatemia is more frequent in patients with low transporter status, so they may 
achieve higher peritoneal P clearance under continuous ambulatory peritoneal dialysis (CAPD) 
regimens. In automated peritoneal dialysis (APD), hyperphosphatemia has been significantly 
associated with a lower number of automated peritoneal dialysis (APD) cycles and a shorter 
duration of nocturnal treatment, with insufficient dwell time. Here, recommended strategies 
to improve P management are increasing dwell times or transfer to CAPD [37]. Recently, Van 
Biesen et al., confirmed that for slow transporters, longer dwells resulted in higher peritoneal 
phosphate clearances, whereas for high transporters, shorter dwells were more optimal [38].
2.3. Fibroblast growth factor 23
FGF23 is a circulating peptide that plays a key role in the control of serum phosphate con-
centrations [4, 39]. It is secreted by bone osteocytes and osteoblasts in response to calcitriol, 
increased dietary phosphate load, PTH, and calcium [40, 41]. In CKD patients, we are faced 
with high level of FGF23 due to its decreased clearance too [4]. FGF23’s primary function is to 
maintain normal serum phosphate concentration by reducing renal phosphate reabsorption 
and indirectly by decreased calcitriol production [42]. FGF23 inhibits the proximal tubular 
expression of 1-alpha-hydroxylase enzyme, leading to decreased calcitriol synthesis [43]. The 
net effect of both hormonal actions is to lower serum phosphate concentration. Increased 
FGF23 is considered as one of the earliest detectable biomarkers of CKD-MBD [44]. Is impor-
tant to underline that treatments used to control CKD-MBD, such as vitamin D analogs and 
calcium-based phosphate binders, stimulate FGF23 production.
FGF23 also suppresses PTH secretion by the parathyroid gland [45]. Klotho expression 
declines progressively with decreasing GFR. Moreover, the decrease in klotho expression on 
hyperplastic parathyroid glands may contribute to the resistance and impaired parathyroid 
suppression by FGF23 [46].
In the PD patient population, data on FGF-23 are scarce. In a study by Isakova et al., the 
authors reported that longer dialysis vintage (R = 0.31), lesser RRF (R = −0.37), and lower renal 
phosphate clearance (R = −0.38) were associated with higher levels of serum FGF-23 [47]. 
Golembiewska et al. in her study highlights the strong positive association between serum 
phosphorus and FGF-23 in patients at the start of PD therapy independently from RRF [48]. It 
is suggested that FGF23 is a more stable marker of phosphate metabolism than PTH or phos-
phate itself, which could help explain its stronger association with outcomes and support the 
further development of FGF23 testing for clinical practice [47].
FGF23 levels are associated with increased risk of cardiovascular disease and mortality in 
patients with CKD [47]. Clinical and experimental studies have shown that FGF23 has a direct 
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pathogenic effect causing left ventricular hypertrophy [29]. However, FGF23 does not seem to 
promote cardiovascular calcification [49].
2.4. Calcitriol
Peritoneal dialysis (PD) patients have a high risk of developing vitamin D deficiency as 
25(OH) vitamin D and the precursor of active vitamin D is lost during dialysis, apart from 
low exposure to sunlight and reduced dermal synthesis.
Plasma calcitriol concentrations generally fall below normal when the GFR is <60 mL/min/1.73 m2 
[8]. This initially happens due to the increase in FGF23 concentration rather than the loss of 
functioning renal mass [50]. However, further with the advanced CKD, hyperphosphatemia in 
addition to increased FGF23 levels contribute to the decline of calcitriol synthesis.
FGF23 decreases the synthesis of calcitriol by suppressing the activity of 1-alpha-hydroxylase, 
which converts 25-hydroxyvitamin D into calcitriol, and by stimulating the 24-hydroxylase 
enzyme, which converts calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites in the 
proximal tubule [43, 51]. Phosphate retention (or perhaps increased phosphate concentrations 
in the proximal tubule) can directly suppress the renal synthesis of calcitriol by inhibiting 
1-alpha-hydroxylase activity [52]. Increased dietary phosphate load and increased calcitriol 
stimulate the secretion of FGF23 predominantly by bone osteocytes.
Low calcitriol concentrations increase PTH secretion by indirect and direct mechanisms:
• Indirect effects on PTH are achieved through decreased intestinal absorption of calcium 
and calcium release from bone, both of which promote the development of hypocalcemia, 
and hypocalcemia stimulates PTH secretion.
• Calcitriol normally acts on the Vitamin D Receptor (VDR) in the parathyroid gland to sup-
press PTH transcription but not PTH secretion. A decrease in calcitriol concentrations low-
ers the number of VDRs in the parathyroid cells. This is reported that can be corrected by 
taking supplementation with calcitriol [53]. The lack of calcitriol and the decreased number 
of receptors may promote both parathyroid cell hyperplasia and nodule formation. At a 
later stage of CKD, we have also the contribution of retained uremic toxins, by decreasing 
both receptor synthesis and the ability of the active hormone-receptor complex to bind to 
vitamin D response elements in the nucleus [54].
2.5. Skeletal resistance to PTH
In CKD, the skeletal resistance to the calcemic action of parathyroid hormone (PTH) is 
reported to contribute to the pathology of secondary hyperparathyroidism [55] due to down-
regulation of PTH receptors induced by the high circulating PTH concentrations; calcitriol 
deficiency and hyperphosphatemia [3, 56].
2.6. Disorders of calcium balance
Studies have suggested that disorders of calcium balance due to CKD-MBD may play a role 
in the high cardiovascular mortality in patients with CKD.
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A positive calcium balance may arise, because the intestinal absorption of calcium overcomes 
the capacity of the diseased kidney for its excretion. The absorbed calcium enters in the 
extracellular space and is distributed in three compartments: blood, soft tissue, and bone. 
Bone contains 99% of total calcium being the major compartment of body calcium. It includes 
mineralized bone sites suggested to be partly mediated by PTH and a rapidly exchangeable 
calcium pool. The regulation of this exchangeable calcium pool might be altered in CKD.
The assessment of calcium balance in dialysis patients (including PD patients) becomes extremely 
complex. It has to take into account not only dietary calcium intake, but also calcium sup-
plement dose, intake of vitamin D analogs (which increase intestinal calcium absorption), 
calcium uptake by soft tissue, stool calcium output, urinary calcium excretion, continuous 
calcium flux from the rapidly exchangeable calcium bone pool, and net bone remodeling 
or turnover, also influx from PD fluid across the peritoneum membrane if a high-calcium 
dialysate is used as a result of the concentration gradient or efflux of it when is used lower 
dialysate calcium [57].
Both hypocalcemia and hypercalcemia are associated with increased mortality in patients 
with CKD [7, 58].
Hypocalcemia is common among CKD patients and may be associated with increased PTH 
secretion and abnormal bone remodeling. Ca is a major regulator of PTH secretion. Minute 
changes in the serum ionized Ca are sensed by a specific Ca membrane receptor (CaSR), 
which is highly expressed on the surface of the chief cells of the parathyroid glands [59]. 
Changes in PTH secretion in response to serum Ca are tightly regulated by the CaSR. The fall 
in serum Ca concentration in CKD, as sensed by the CaSR, is a potent stimulus to the release 
of PTH. When Ca level goes persistently low, it appears to directly increase PTH mRNA 
concentrations via posttranscriptional actions and stimulates the proliferation of parathyroid 
cells over days or weeks [60].
A positive calcium balance, hypercalcemia, inhibits the secretion of PTH and stimulates the 
development of adynamic bone disease in patients undergoing PD. The risk of protein energy 
wasting (PEW), often referred as malnutrition, is higher especially in the elderly PD patients. 
This is associated with reduced bone mass [61] and increase fracture risk in this population 
[1, 62]. In addition, hypercalcemia has been implicated in the pathogenesis of extraskeletal 
calcification and is evaluated as an important factor in progression of calcification.
2.7. Vascular calcifications
In the last decades, although the number of peritoneal dialysis (PD) patients is increased, 
most of the studies related to vascular calcification development are mainly focused on HD 
population. The prevalence of cardiac valvular calcification is reported to be high in both 
modalities, ranges from 32–47% in PD patients [1, 63] to 19–84% in hemodialysis patients [64, 65] 
and greatly contribute on high cardiovascular mortality in this population [2, 66–68].
Recent studies suggest that vascular calcification is a process that involves more than simple 
precipitation of calcium and phosphate. A complex series of events causes predisposed 
vascular smooth muscle cells to differentiate into osteoblasts or bone forming cells. Chronic 
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inflammation is one of the predisposing factors too. Serum fetuin-A, which is a potent inhibi-
tor of extraskeletal calcification, is reduced in CKD patients with severe vascular calcification. 
A list of contributing factors in vascular/valve calcifications in PD is present in (Table 2).
The increased prevalence of risk factors for atherosclerosis [69], disordered mineral metab-
olism with a high calcium load and/or uncontrolled phosphate resulting in poor calcium-
phosphate balance, as well as the loss of inhibitors of calcifications are considered largely 
responsible for the higher prevalence of valve and vascular calcification in dialysis patients 
[70] compared to age- and sex-matched individuals without the evidence of renal disease [71].
The treat-to-goal study revealed that after 3 years in dialysis, 83% of patients had vascular 
calcifications underlining the importance of the evaluation and control of all the parameters 
of CKD-MBD [68].
3. Diagnostic workup for disorders of bone and mineral metabolism 
in patients under peritoneal dialysis treatment
As stated above, regarding bone metabolism and morphology, differences may exist 
between chronic hemodialysis and peritoneal dialysis treatment. These differences apart 
from preservation of renal function are mainly linked to deficiency of vitamin D, which is 
lost in peritoneal fluid and to and poor adherence to oral vitamin D therapy in PD [72]. 
The latest guideline with new recommendations was provided by KDIGO in 2017, in order 
to better reflect the complex interaction between CKD-MBD laboratory parameters [73]. 
It is important to emphasize that there are no separate or different recommendations for 





Higher dose of Vit D analogs





High level of sclerostin
Low levels of fetuin-A
Table 2. Contributing factors to vascular/valve calcification in PD patients.
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3.1. Biochemical components: Ca, P, PTH, ALP, bALP, 25(OH)D
In the above mentioned guidelines in CKD Grade 5 in Dialysis (G5D) [73], it is stated with a 
nongraded level of recommendation, that it is reasonable to base the frequency of monitor-
ing serum calcium, phosphate, and PTH in the presence and magnitude of abnormalities. 
Guideline evaluated as reasonable measurement of serum calcium and phosphate every 
1–3 months, PTH every 3–6 months, and alkaline phosphatase activity every 12 months or 
more frequently in the presence of elevated PTH. The guideline also had a very weak (2D 
level) suggestion that instead of calcium-phosphate (CaxP) product, values of serum calcium 
and phosphate, evaluated together should be used in clinical practice.
PTH is a hormone with high biological variation because of feedback control and its short 
half-life. For instance, 26 blood samples are required in hemodialysis patients to determine 
the individual homeostatic set-point (within 10%) [74]. In PD patients, it is confirmed the 
U-shaped curve association between mortality and PTH concentration [75].
Alkaline phosphatase. The use of total alkaline phosphatase (ALP) as a biomarker in CKD-
MBD is considered limited by its nonspecificity for bone disease, as only approx. 50% of blood 
activity is attributable to bone ALP. In contrast to the U-shaped curve for mortality and time-
averaged PTH confirmed in PD patients [76], higher ALP activity (even within high-normal 
ranges) was found to be more linearly and independently associated with increased all cause 
and cardiovascular mortality in this population [77, 78]. In studies reporting a relationship 
between ALP and mortality in hemodialysis patients, it has been implied that the relationship 
is driven by vascular calcification mediated by the bone fraction of ALP [79].
Bone ALP is strongly and independently related to BMD, not accumulated with declining 
GFR and its concentration reflects directly osteoblastic activity [80], providing a “living 
biopsy” of bone activity. Most importantly, its biological variation is almost half that of PTH 
[81]. It is shown that higher b-ALP is an independent predictor of all-cause mortality in male 
HD patients [82] and high activities of b-ALP are strongly associated with cardiovascular 
mortality in dialysis patients, including PD population [83].
25(OH)D. Peritoneal dialysis (PD) patients have a high risk of developing vitamin D deficiency 
as 25(OH) vitamin D (the precursor of active vitamin D), is lost during dialysis. Vitamin D 
(25(OH) vitamin D) is measured to detect deficiency/insufficiency status. Defects of mineral-
ization are presumably because of osteomalacia and hip fractures that associate its low levels 
[84]. Increase in mortality and hospitalization for patients on dialysis with severe 25-OH vita-
min D deficiency was found [85] in a prospective cohort study. 2017 KDIGO guideline sug-
gests (2C) in G5D patients, that 25(OH)D (calcidiol) levels might be measured, and repeated 
testing might be performed, determined by baseline values and therapeutic interventions.
In order to facilitate the appropriate interpretation of biochemistry data, it is moderately 
strongly recommended (1B) that clinical laboratories inform clinicians of the assay method 
or any change in method used, sample source (plasma or serum), or any specific relevant 
information [73]. It is also recommended (1C) that therapeutic decisions to be based on trends 
rather than on a single laboratory value and to take into account all available CKD-MBD 
parameters [73].
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3.2. Biomarkers and tests for diagnosis of bone abnormalities in peritoneal dialysis
Parathyroid hormone (PTH) and total bone specific alkaline phosphatase (b-ALP) are bio-
markers currently used in clinical practice despite some assay limitations. They may reflect 
bone turnover and bone formation. In an individual patient, no single biomarker or in com-
bination is sufficient to diagnose low, normal, and high bone turnover although whole PTH, 
iPTH, and b-ALP levels are found associated with bone turnover. This was the conclusion 
of a recent cross-sectional retrospective diagnostic study of biomarkers and bone biopsies in 
492 dialysis patients, with the objective to determine the predictive value of PTH [both intact 
PTH (iPTH) and total PTH], bone-specific alkaline phosphatase (b-ALP), and amino-terminal 
propeptide of type 1 procollagen (P1NP) as markers of bone turnover [86]. Rather than simple 
measurement of PTH, the continued use of trends in PTH is encouraged to guide therapy [73].
BMD testing. Identifying biomarkers and imaging test for non-invasive evaluation of patients 
at fracture risk is very important in dialysis patients, which in their 40s have a relative risk of 
hip fracture 80-fold that of age and sex-matched controls [87]. Multiple new prospective stud-
ies conducted in patients with CKD G3a-G5D demonstrated that lower dual-energy X-ray 
absorptiometry bone densitometry (DXA BMD) predicts incident fractures and the associa-
tions are comparable to the ones seen in the absence of CKD [76–79, 88]. In the light of these 
studies, in patients with G5D with the evidence of CKD-MBD and/or risk factors for osteo-
porosis, KDIGO guideline has a moderately strong suggestion for performing BMD testing 
to assess fracture risk, if results will impact treatment decisions (2B level) [73]. A DXA BMD 
result might also impact the decision to perform a bone biopsy [73].
Bone biopsy. In many centers, experience in performing and evaluating bone biopsies is lim-
ited [89]. In one side, DXA BMD does not distinguish among types of renal osteodystrophy. 
On the other side, (considering the short half-lives of the circulating biomarkers and the long 
(3–6 months) bone remodeling cycle), it is not surprising that cross-sectional studies have 
shown conflicting and non-conclusive data on the biomarkers use to predict underlying bone 
histology [89]. Biomarkers resulted of limited diagnostic use because of poor sensitivity and 
specificity. Although they correlate with some histomorphometric measurements in bone 
biopsy, studies have shown only modest positive predictive value of circulating PTH or bone-
specific alkaline phosphatase levels for detection of states of high and low bone turnover, 
especially for adynamic bone disease [90–94].
Bone biopsy is the gold standard for the assessment of renal osteodystrophy, which is a 
component of the bone abnormalities of CKD-MBD. Its goals are to determine high- or low-
turnover disease, identify a mineralization defect (both influencing treatment decisions), and 
rule out atypical or unexpected bone pathology. When trends in PTH are inconsistent, or in 
patients with progressively decreased BMD despite standard therapy, with unexplained frac-
tures, refractory hypercalcemia, suspicion of osteomalacia or an atypical response to standard 
therapies for elevated PTH, a bone biopsy should be considered [73]. In the recent KDIGO 
guideline, it is stated that it is reasonable to perform a bone biopsy, if knowledge of the type 
of renal osteodystrophy will impact treatment decisions [73]. The bone biopsy is undertaken 
with a trocar preferably in the iliac crest. Double labeling with tetracycline according to a 
protocol is required to assess the turnover.
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Bone turnover markers. During skeletal metabolic activity, bone turnover biomarkers are 
released into circulation and can be measured in the serum.
• Serum marker of bone resorption in which levels are not dependent in GFR (not renally 
cleared) is serum tartrate-resistant acid phosphatase (TRAP5b). Renally cleared markers 
of bone resorption are serum amino-terminal cross-linking telopeptide of type 1 collagen 
(s-NTX), serum carboxy-terminal cross-linking telopeptide of type 1 collagen (s-CTX), and 
carboxy-terminal crosslinking telopeptide of type 1 collagen (s-ICTP or CTX-MMP).
• Serum markers of bone formation. Serum alkaline phosphatase, bone specific alkaline 
phosphatase, and procollagen type IN propeptide (s-PINP) are not dependent in GFR and 
serum osteocalcin, procollagen type IC propeptide (s-PICP) are renally cleared [95]. 2017 
guideline suggests not to routinely measure bone-derived turnover markers of collagen 
synthesis and breakdown (2C) [73]. Keeping in consideration their renal and dialytic elimi-
nation, those biomarkers and circulating fragments need to be studied and re-evaluated 
prospectively in CKD and ESRD population [95].
• FGF23. FGF23 may be a more stable marker of phosphate metabolism in ESRD compared 
to PTH or serum phosphate. Differently from parathyroid hormone (PTH), which fluctu-
ates diurnally, acutely in response to changes in serum calcium and postprandially, FGF23 
levels show minimal circadian and postprandial fluctuations in CKD [96, 97]. Despite no 
consensus about the ideal FGF23 assay, FGF23 showed significantly less within-subject 
variability compared to PTH and phosphate (measured contemporaneously). A single 
measurement of FGF23 could more accurately assess the phosphate metabolism disorder 
compared to markers actually in use. Prospective studies found elevated FGF23 to inde-
pendently associate with mortality in incident hemodialysis patients [2, 98]. Accounting 
together these data further support usage of FGF23 testing.
3.3. Diagnosis of vascular abnormalities of CKD-MBD
An increasing number of data have shown the very high prevalence of cardiovascular 
calcification in dialysis patient population, including patients receiving long-term perito-
neal dialysis treatment [63–69, 99]. Electron beam computerized tomography (EBCT) or 
multi-slice computerized tomography (MSCT) can measure coronary artery and valvular 
calcifications, but other more widely available tests as lateral abdominal X-ray and echocar-
diography also can measure calcifications. Vascular and valvular calcifications are impor-
tant factors for determining the prognosis of patients on CAPD [100] and patients with 
confirmed vascular or valvular calcifications are at highest cardiovascular risk [68, 101]. 
This is the rationale of the use of vascular and valvular calcification information to guide the 
management of CKD-MBD. Despite the long and ongoing debate [102–105] about screening 
of ESRD population, according to 2017 KDIGO guideline, based on low quality of evidence 
(2C), a lateral abdominal radiograph and an echocardiogram can, respectively, be used (as 
alternatives to CT-based imaging) to detect the presence of vascular/valvular calcification 
in patients with G5D [73].
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4. Treatment of CKD-MBD in patients on peritoneal dialysis
4.1. Treatment of CKD-MBD targeted at lowering high serum phosphate and 
maintaining serum calcium
4.1.1. Control of phosphorus and calcium in peritoneal dialysis patients
As outlined above, the risk of hyperphosphatemia has been clearly shown for population 
treated with both hemodialysis and peritoneal dialysis [31, 38, 106]. The role of hyperphos-
phatemia as a principle actor in the development and progression of vascular calcification has 
been well documented in this population [70].
Vascular calcifications are predictive of higher morbidity and mortality in dialysis patients. 
The main target of pharmacological research in the field has moved from bone toward the 
cardiovascular apparatus [107]. The control of serum phosphorus at all stages of CKD is con-
sidered one of the more important aspects to improve clinical outcomes in CKD-MBD.
On the other side, the complex relationship between abnormal CKD-MBD parameters sug-
gests the need of optimal control of all CKD-MBD parameters in order to modify the mortality 
risk among PD patients and improve clinical outcomes.
Phosphate balance in dialysis patients depends on phosphate intake, absorption (minus phos-
phate binding), and dialysis removal. KDIGO guidelines in 2017 suggest lowering elevated 
phosphate levels toward the normal range in dialysis patients [73].
• Dietary restriction of phosphorus is an important part of phosphate control treatment in all 
dialysis modalities. The impact of phosphorus intake on patients is clear: higher levels of 
dietary phosphorus intake and a higher ratio of dietary phosphorus to protein are associ-
ated with an increased risk of death [3, 28, 108]. But because of other important risk factors 
for patient mortality and morbidity, such as malnutrition and hypoalbuminemia, dietary 
restriction may not be successful alone and cannot be effective without the help of other 
treatment measures, mainly the use of phosphate binders.
• Type of dialysis may also be an important factor in the adequacy of phosphorus control in 
dialysis patients [109, 110]. Chronic PD as a continuous dialysis modality has an expected 
theoretical superiority over intermittent hemodialysis [32–35].
Compared to hemodialysis (HD), patients undergoing PD appear to have an increased preva-
lence of low turnover bone disease defined as adynamic bone disease (ABD) [16–23, 111]. In 
PD, as discussed above, calcium transfer across the peritoneum is regulated by two different 
mechanisms known like diffusion and convection. These processes depend on serum calcium 
levels, calcium concentration in the dialysate, and dialysis dextrose concentration [8].
Moraes et al. reported that in patients with PTH < 150 pg/mL conversion to low calcium 
solutions (2.5 mEq/L) appears to be a simple and effective strategy to bring PTH levels to the 
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range determined by current guidelines when compared with 3.5 mEq/L calcium PD solu-
tions [112]. This supports the finding of Spasovski et al. in HD patients where the lower dialy-
sate calcium (1.25 mmol/l [2.5 mEq/l]) was found to improve bone and mineral parameters 
compared with the higher concentration of 1.75 mmol/l (3.5 mEq/l) in patients with adinamic 
bone disease [113].
There is no data on Ca balance in PD patients, so the safety limit for an elemental calcium 
dose in PD patients is currently uncertain but based on the opinion of Wang the maximal 
additional elemental calcium given daily in the form of calcium-containing phosphate binder 
should be kept to not more than 800 mg to avoid calcium overload [114]. Patients with a 
negative dialysate calcium balance may show an overall positive calcium balance, if they are 
concomitantly treated with calcium-containing phosphate binders, especially when coupled 
with vitamin D [114].
It is important to emphasize that the KDIGO 2009 guidelines recommend a 1.25–1.50 calcium 
dialysate for both HD and PD and this is an additional consideration that should be taken into 
account when choosing a phosphate binder [1].
Without phosphate-binding therapy, all patients undergoing PD are in a positive phosphorus 
balance, unless they are severely malnourished. As mentioned before, the reduction of oral 
phosphate intake, an adequate dialysis schedule and the use of intestinal phosphate binders 
are three strategies used to manage hyperphosphatemia in dialysis patients [114]. Inevitably, 
in the long term, patients rarely observe rigid dietary phosphate restriction, especially in the 
context of PD where a higher number of patients are prescribed a less restrictive diet with a 
higher content of dietary protein [115].
Phosphate binders are essential in control of phosphate overload and in the improvement of 
outcomes in peritoneal dialysis patients. Phosphate binders are used for their binding actions 
to reduce the absorption of phosphorus by the gastrointestinal lumen. First, it should be 
stressed that patient compliance is fundamental not only in limiting dietary intake of phos-
phorus but also in adhering to the prescribed protocol of phosphate binder administration, 
frequently linked to the number of pills the patient is required to take and the degree of 
gastric tolerance of the product prescribed.
There is insufficient evidence that any specific phosphate binder significantly impacts patient-
level survival. The decision to use a phosphate binder should be followed by consideration 
of which currently available phosphate-binding agent is suitable for the patient. Ideally, a 
phosphate binder should effectively bind dietary phosphate regardless of pH have minimal 
systemic absorption, few side effects, good palatability, a low pill burden, and be available 
at a low cost [116]. Traditionally, phosphate binders are classified into calcium-containing 
phosphate binders and calcium-free phosphate binders.
4.1.2. Calcium-containing phosphate binders
Calcium-containing phosphate binders are available in two formulations: calcium carbonate 
and calcium acetate. Efficacy of calcium-based phosphate binders is known to be clinically sat-
isfactory, especially when combined with adequate dialysis and dietary measures. Nowadays, 
calcium salts are considered not free of side effects. Great concern has been expressed about 
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their effect on raising serum calcium levels, especially when used in association with vitamin 
D or high calcium dialyzing solutions.
High calcium balance may over suppress PTH, exiting in a state of adynamic bone disease 
(ABD), which is as dangerous as a high bone turnover state [114]. Furthermore, the excess of 
calcium may lead to tissue and vascular calcifications, increasing cardiovascular mortality. 
Regarding the use of calcium-based phosphate binders in PD patients, there are limited data 
available. The majority of studies comparing calcium salts and sevelamer are performed in 
hemodialysis patients. These studies confirm the efficacy of calcium salts as phosphate bind-
ers and the potential role of them in developing calcifications.
Calcium salts should be administered carefully, considering the clinical status of each patient. 
KDIGO guidelines suggest restricting the dose of calcium salts in the presence of arterial cal-
cification and/or adynamic bone disease and/or if serum PTH levels are persistently low [1].
4.1.3. Calcium-free phosphate binders
Aluminum salts were largely used as calcium-free phosphate binders, but this treatment was 
abandoned when cases of systemic aluminum toxicity were reported [117].
Sevelamer is a calcium- and aluminum-free phosphate binder, developed for hyperphosphate-
mia management in dialysis patients. There are also few data regarding sevelamer administra-
tion in PD patients. A study comparing the efficacy of sevelamer and calcium acetate showed the 
same efficiency of both treatments in control of serum phosphorus and PTH [118]. This study 
also evaluated the association between sevelamer administration and risk of peritonitis in PD 
patients, because it has been thought that a higher rate of diarrhea and constipation induced by 
sevelamer might increase the risk of peritonitis caused by Gram-negative microorganisms due 
to trans-mural migration of bacteria. Although peritonitis occurred in 11% of the patients in the 
sevelamer group and in 4% of the patients on calcium-containing phosphate binders, no signifi-
cant increase in the risk of peritonitis was found [118]. Another study performed in PD patients 
in Canada showed the efficacy of sevelamer in ameliorating CKD-MBD parameters [119].
Lanthanum carbonate is another nonaluminum- and noncalcium-containing phosphate 
binder that has more recently become available for the management of hyperphosphate-
mia in dialysis patients. Unfortunately, less evidence and studies are available for patients 
undergoing PD [114]. An open, noncomparative study in patients with hyperphosphatemia 
undergoing continuous ambulatory PD evaluated safety and efficacy of lanthanum carbonate 
to reduce serum phosphate levels [120]. This study showed that lanthanum carbonate was 
generally well tolerated. Furthermore, majority of the patients reached the therapeutic target 
level in 2 months at doses between 750 and 2250 mg, suggesting that the efficacy dose was 
lower than that for HD patients.
A novel noncalcium iron-based phosphate binder, sucroferric oxyhydroxide is introduced for 
the management of hyperphosphatemia in dialysis patients. It is formulated as a chewable 
tablet containing 500 mg iron. Long-term efficacy and tolerability of the iron-based phosphate 
binder, sucroferric oxyhydroxide, was compared with that of sevelamer carbonate in an open-
label Phase III extension study [121]. A representative proportion (9.3%) of patients receiving 
peritoneal dialysis was included in this long-term analysis of phosphate binders. Extension 
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study data demonstrate that the efficacy of sucroferric oxyhydroxide for controlling serum 
phosphorus concentration was robust, maintained over the long-term (1 year) and similar 
to that of sevelamer. Sucroferric oxyhydroxide was generally well tolerated over 1 year. The 
pill burden over 1 year of treatment was 62% lower with sucroferric oxyhydroxide than with 
sevelamer [121].
4.2. Treatment of secondary hyperparathyroidism in PD patients
Though the prevalence of secondary hyperparathyroidism (SHP) and the related mineral 
metabolism changes have been reported at almost the same rate in peritoneal dialysis as in 
hemodialysis patients, PD patients have a higher prevalence of adynamic bone disease sug-
gesting that their bone is less sensitive for a given level of PTH [122].
It has also been widely reported that PD patients have lower vitamin D levels as compared 
with the HD patients [123]. Among the multiple causes which might explain the higher preva-
lence of vitamin D deficiency in PD patients, the peritoneal loss of vitamin D binding protein 
probably plays an overwhelming role.
It is suggested to correct vitamin D deficiency, using low doses of either cholecalciferol or 
calcifediol (800–100 UI/day), by adding calcitriol or paricalcitol only when, after the first two 
described steps, the PTH levels are stable at 450–500 pg/mL or show a clear increasing trend 
in the absence of relatively high calcium (>10.0 mg/dl) and/or phosphorus (>5.5 mg/dl) levels 
[122]. In these latter cases, it is suggested to start treatment with cinacalcet.
Most of studies on administration of calcimimetics in dialysis are performed in hemodialysis 
patients. Few studies that are PD have a very limited number of patients. So, most of the 
recommendations for peritoneal dialysis patients are simply transferred from the HD experi-
ences. The calcimimetic cinacalcet was approved by the US Food and Drug Administration 
in 2004 and by European Committee for Medical Products for Human Use in 2005 to treat 
secondary hyperparathyroidism in patients on dialysis.
Cinacalcet acts directly upon the parathyroid cell calcium-sensing receptor (CaR). Upon 
binding CaR, cinacalcet allosterically increases its sensitivity to extracellular calcium thus 
suppressing PTH secretion without increasing serum calcium and phosphate levels [124]. A 
retrospective study was performed at a single PD unit based on 27 patients with moderate 
to severe SHPT (PTHi > 500 pg/mL with normal or elevated serum calcium levels) who were 
treated with cinacalcet. Cinacalcet was started due to the lack of response with conventional 
treatment: diet, phosphate binders, and vitamin D or inability to treat with vitamin D due to 
hyperphosphatemia >5.5 mg/dL or hypercalcemia >10.5 mg/dL [125]. This study showed that 
cinacalcet was a safe but not effective therapy in moderate to severe SHPT in PD patients. The 
gastrointestinal adverse factors made impossible the prescription of higher doses of cinacalcet 
and an eventual benefit of this therapy at higher doses in SHPT was impossible to evaluate.
On contrary with these conclusions were results of another study performed by Portoles 
et al. in PD patients. They evaluated efficiency and safety of cinacalcet in eighteen patients 
undergoing more than 4 months on PD with a severe SHPT (PTH > 500 pg/mL) resistant to 
conventional treatment with diet, chelants and vitamin D, in a prospective open-label study 
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[126]. The authors concluded that the addition of cinacalcet to conventional treatment in PD 
patients with resistant SHPT has improved the achievement of targets of K/DOQI guidelines 
and has been reasonably safe.
Lindberg et al. [127] evaluated a total of 395 patients on dialysis (349 on HD and 46 on PD). 
Two hundred and ninetyfour patients (260 HD and 34 PD) were treated with once-daily oral 
cinacalcet (titrated from 30 to 180 mg/day), while the remaining 101 patients (89 HD, 12 PD) 
were on placebo in addition to the ongoing standard therapy. This study confirmed that cina-
calcet induced a more pronounced reduction of PTH in a larger percentage of patients as com-
pared with standard therapy, with no major difference in the percentage of patients on HD 
and on PD treatment achieving a PTH level lower than 250 pg/mL (39 and 38%, respectively).
Cinacalcet treatment was associated with a slight, but significant, decrease in both calcium and 
phosphorus concentrations as compared with patients treated with the standard therapy only. 
Gastrointestinal symptoms were reported to be the most frequent adverse effects. However, 
no difference was observed between HD and PD patients in the incidence or type of the 
reported side events. A severe form of SHP is an unusual finding in PD patients. Furthermore, 
the control of phosphate is usually better in PD than in HD patients, at least until the residual 
diuresis is maintained. Another specific characteristic of patients treated with PD is the higher 
tendency to status of vitamin D deficiency which might make these patients more prone to 
hypo rather than hypercalcemia. For all these reasons, it is possible to predict that the need 
for the use of the most recent and potent drugs which are nowadays available for the control 
of SHP, including cinacalcet, might be lower in PD than in HD patients [122].
5. Nomenclature
The recommendation on diagnosis and management of CKD-MBD presented in this chapter 
are based on KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, 
prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
The level of recommendations presented in these guidelines are:
Level 1—we recommend; Level 2—we suggest; the ungraded recommendations are generally 
written as simple declarative statements, but are not meant to be interpreted as being stronger 
recommendations than Level 1 or 2 recommendations.
Quality of evidence presented in these guidelines:
Meaning A High: we are confident that the true effect lies close to that of the estimate of the 
effect.
B Moderate: the true effect is likely to be close to the estimate of the effect, but there is a pos-
sibility that it is substantially different.
C Low: The true effect may be substantially different from the estimate of the effect.
D Very low: The estimate of effect is very uncertain and often will be far from the truth.
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